These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34782700)

  • 1. Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways.
    Hongo H; Kosaka T; Suzuki Y; Mikami S; Fukada J; Oya M
    Sci Rep; 2021 Nov; 11(1):22284. PubMed ID: 34782700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening.
    Hongo H; Kosaka T; Suzuki Y; Oya M
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):59-66. PubMed ID: 34593983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer.
    Hongo H; Kosaka T; Oya M
    Cancer Sci; 2018 Sep; 109(9):2937-2945. PubMed ID: 29989268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Begemann D; Wang Y; Yang W; Kyprianou N
    Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
    Watanabe H; Kawakami A; Sato R; Watanabe K; Matsushita Y; Miyake H
    Anticancer Res; 2021 Aug; 41(8):3753-3758. PubMed ID: 34281834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
    Hishida S; Kawakami K; Fujita Y; Kato T; Takai M; Iinuma K; Nakane K; Tsuchiya T; Koie T; Miura Y; Ito M; Mizutani K
    Prostate; 2021 Jun; 81(9):592-602. PubMed ID: 33905554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.
    Garrido MF; Martin NJ; Bertrand M; Gaudin C; Commo F; El Kalaany N; Al Nakouzi N; Fazli L; Del Nery E; Camonis J; Perez F; Lerondel S; Le Pape A; Compagno D; Gleave M; Loriot Y; Désaubry L; Vagner S; Fizazi K; Chauchereau A
    Clin Cancer Res; 2019 Jan; 25(2):710-723. PubMed ID: 30322877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer.
    Hoang B; Ernsting MJ; Tang WS; Bteich J; Undzys E; Kiyota T; Li SD
    Cancer Lett; 2017 Dec; 410():169-179. PubMed ID: 28965854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
    Pourpak A; Landowski TH; Dorr RT
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1109-17. PubMed ID: 17351106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
    Kirk JS; Schaarschuch K; Dalimov Z; Lasorsa E; Ku S; Ramakrishnan S; Hu Q; Azabdaftari G; Wang J; Pili R; Ellis L
    Oncotarget; 2015 Feb; 6(5):3136-46. PubMed ID: 25605014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
    Chao OS; Goodman OB
    Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming TRAIL-resistance by sensitizing prostate cancer 3D spheroids with taxanes.
    Grayson KA; Jyotsana N; Ortiz-Otero N; King MR
    PLoS One; 2021; 16(3):e0246733. PubMed ID: 33661931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
    Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
    Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer.
    Sekino Y; Han X; Kawaguchi T; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Yasui W; Matsubara A
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
    Lombard AP; Liu C; Armstrong CM; Cucchiara V; Gu X; Lou W; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Oct; 16(10):2257-2266. PubMed ID: 28698198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer.
    Archer M; Begemann D; Gonzalez-Kozlova E; Nepali PR; Labanca E; Shepherd P; Dogra N; Navone N; Kyprianou N
    Mol Cancer Res; 2024 Aug; 22(8):730-745. PubMed ID: 38648082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
    de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
    Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer.
    Lin JZ; Hameed I; Xu Z; Yu Y; Ren ZY; Zhu JG
    Oncol Rep; 2018 Oct; 40(4):2242-2250. PubMed ID: 30066906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.